Designated Organic Active Ingredient Containing (doai) Patents (Class 514/1)
  • Patent number: 11321885
    Abstract: The present disclosure describes systems, methods, and non-transitory computer readable media for generating and providing a causal-graph interface that visually depicts causal relationships among dimensions and represents uncertainty metrics for such relationships as part of a streamlined visualization of a causal graph. The disclosed systems can determine causality among dimensions of multidimensional data and determine uncertainty metrics associated with individual causal relationships. Additionally, the disclosed system can generate a visual representation of a causal graph with nodes arranged in stratified layers and can connect the layered nodes with uncertainty-aware-causal edges to represent both the causality between the dimensions and the uncertainty metrics.
    Type: Grant
    Filed: October 29, 2020
    Date of Patent: May 3, 2022
    Assignee: Adobe Inc.
    Inventors: Fan Du, Xiao Xie, Shiv Kumar Saini, Gaurav Sinha, Ayush Chauhan
  • Patent number: 11225660
    Abstract: This disclosure relates to the use of miRNA-483 and its target genes, UBE2C, pVHL and HIF1alpha, in managing the treatment of cardiovascular and inflammatory diseases. In certain embodiments, this disclosure relates to pharmaceutical compositions comprising a miR-483 mimic and/or an HIF inhibitor and a pharmaceutically acceptable excipient for use in treating or preventing a vascular disease or condition. In certain embodiments, the miR-483 mimic is a double stranded nucleobase polymer or an expression vector that expresses mature human miR-483-5p and miR-483-3p sequences or operable fragments and variants.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: January 18, 2022
    Assignee: Emory University
    Inventors: Hanjoong Jo, Joan Fernandez Esmerats, Nicolas Villa-Roel
  • Patent number: 11214609
    Abstract: This disclosure provides non-naturally occurring collagen and elastin molecules. The non-naturally occurring collagens and elastins include truncated collagens, truncated elastins, as well as fusion proteins thereof. The non-naturally occurring collagen and elastin are useful in foods, cosmetics and many other products and uses.
    Type: Grant
    Filed: April 2, 2020
    Date of Patent: January 4, 2022
    Assignee: GELTOR, INC.
    Inventors: Nikolay Ouzounov, Alexander Lorestani, Monica Bhatia
  • Patent number: 11205502
    Abstract: Provided are a processing method and a processing apparatus for efficacy of a combined drug. The processing method includes: obtaining dose-effect curve band of expected additive effect of the combined drug; obtaining actual dose-effect relationship curve formed by actual effect value of the combined drug with a dose change of one target component drug in the combined drug; comparing a positional relationship between the actual dose-effect relationship curve and the dose-effect curve band; and outputting the efficacy of the combined drug as a synergistic effect when the actual dose-effect relationship curve is located above the dose-effect curve band, outputting the efficacy of the combined drug as an antagonistic effect when the actual dose-effect relationship curve is located below the dose-effect curve band, and outputting the efficacy of the combined drug as an additive effect when the actual dose-effect relationship curve is located within a range of the dose-effect curve band.
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: December 21, 2021
    Assignee: Institute of radiation medicine, academy of military medical sciences, PLA.
    Inventors: Shoujun Yuan, Linna Li, Dexuan Yang
  • Patent number: 11154486
    Abstract: A composition and a method of washing urushiol off the surface of human skin. The composition includes a first solely C12 surfactant and a second solely C12 surfactant that are each in a non-buffered composition and the composition is free of each of the following: (1) any nonylphenol ethoxylate, (2) any pharmaceutically active drug or prodrug, or (3) any salt that affects the functional characteristics of either of the solely C12 surfactants.
    Type: Grant
    Filed: February 19, 2020
    Date of Patent: October 26, 2021
    Assignee: WILLIAM M. YARBROUGH FOUNDATION
    Inventor: Michael Edward Silver
  • Patent number: 11154501
    Abstract: A composition comprises a low-solubility ingredient having a particle size of at most 10 ?m dispersed in a solvent. The ingredient is present in an amount greater than the saturation limit of the ingredient in the solvent. The composition passes the freeze-thaw cycling test.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: October 26, 2021
    Assignee: Nanophase Technologies Corporation
    Inventor: Harry W. Sarkas
  • Patent number: 11124781
    Abstract: Provided are fusion proteins between p97 (melanotransferrin) and iduronate-2-sulfatase (IDS), and related compositions and methods of use thereof, for instance, to facilitate delivery of IDS across the blood-brain barrier (BBB) and/or improve its tissue penetration in CNS and/or peripheral tissues, and thereby treat and/or diagnose Hunter Syndrome (Mucopolysaccharidosis type II; MPS II) and related lysosomal storage disorders, including those having a central nervous system (CNS) component.
    Type: Grant
    Filed: June 22, 2019
    Date of Patent: September 21, 2021
    Assignee: Bioasis Technologies, Inc.
    Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
  • Patent number: 11090305
    Abstract: The invention relates to therapeutic applications for compositions that reduce the level of oxidative stress on cells in vivo or in vitro. The invention describes methods for improving the therapeutic properties of stem cells. The invention also provides combination therapies that are useful to balance the oxidative microenvironment of cells in vivo or in vitro.
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: August 17, 2021
    Assignee: University of Massachusetts
    Inventor: Louis M. Messina
  • Patent number: 11013750
    Abstract: Methods of treating a condition resulting in nociceptive pain are provided. The method includes the step of administering to a mammal a therapeutically effective amount of a compound selected from the group consisting of diacetyl salicylic acid (DAS), aurin tricarboxylic acid (ATA), aurin quadracarboxylic acid (AQA), aurin hexacarboxylic acid (AHA), and/or a combination thereof.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: May 25, 2021
    Assignee: Aurin Biotech Inc.
    Inventors: Patrick L. McGeer, Moonhee Lee, Krista Kennedy, Edith G. McGeer, Douglas N. Bell
  • Patent number: 10988522
    Abstract: Described herein is a novel cyclotide able to activate the unique receptor of angiotensin-(1-7) (AT1-7), the MAS1 receptor. This cyclotide may be used in the treatment of cancer and myocardial infarction.
    Type: Grant
    Filed: December 26, 2018
    Date of Patent: April 27, 2021
    Assignee: UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventors: Julio A. Camarero Palao, Teshome L. Aboye, Kathleen E. Rodgers
  • Patent number: 10953036
    Abstract: Compositions and methods for modulating HIF-2? to meditate of hypoxia signaling in satellite cells and applications thereof for improving skeletal muscle generation and repair are provided. For example, methods of enhancing, increasing, accelerating or/and otherwise improving skeletal muscle generation or regeneration in a subject in need thereof are disclosed. In some embodiments, the methods include administering the subject an effective amount of HIF-2? inhibitor. The HIF-2? inhibitor can be effective to, for example, increase muscle satellite cell proliferation, differentiation, or a combination thereof in a subject. Composition and methods for improving respiration, and reducing or preventing the development or progression of fibrosis are also provided. The disclosed compositions and methods are particularly useful for treating muscular dystrophies, myopathies, and other muscle-related diseases and disorders.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: March 23, 2021
    Assignee: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
    Inventors: Hang Yin, Liwei Xie, Amelia Yao-Ye Yin
  • Patent number: 10918633
    Abstract: In one aspect, a coronavirus is treated by administering a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In another aspect, oxidative stress is reduced in an individual suffering from a coronavirus by administering a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In another aspect, mitochondrial reactive oxygen species (mtROS) are inhibited in an individual suffering from a coronavirus by administering a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In one example, the coronavirus is Covid-19.
    Type: Grant
    Filed: February 17, 2020
    Date of Patent: February 16, 2021
    Assignee: MyMD Pharmaceuticals, Inc.
    Inventor: Jonnie R. Williams
  • Patent number: 10912761
    Abstract: The present invention concerns methods and compositions involving inhibitors and of RAD51, a protein involved in homologous recombination. In some embodiments, there are methods for sensitizing cells to the effects of DNA damaging agents, which can have particular applications for cancer patients. In some embodiments of the invention, the RAD51 inhibitor is a small molecule that directly affects RAD51 activity, such as its ability to promote filament formation.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: February 9, 2021
    Assignee: THE UNIVERSITY OF CHICAGO
    Inventors: Philip P. Connell, Brian Budke, Jay H. Kalin, Michal Pawlowski, Alan P. Kozikowski
  • Patent number: 10786519
    Abstract: This document provides methods and materials for treating HIV infections. For example, methods and materials for using one or more proteosome inhibitors in combination with one or more other agents to treat HIV infections are provided.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: September 29, 2020
    Assignee: Mayo Foundation for Medical Education and Research
    Inventor: Andrew D. Badley
  • Patent number: 10745472
    Abstract: The present invention relates to a composition which is for preventing and treating eye diseases and comprises an anti-angiopoietin-2 (Ang2) antibody and, more specifically, to a novel use of an anti-Ang2 antibody as an agent for preventing or treating eye diseases, wherein the anti-Ang2 antibody is specifically coupled to Ang2, is coupled to a Tie2 receptor together with Ang2, and has improved affinity. The composition according to the present invention can be usefully used to develop a treatment agent for macular degeneration, diabetic retinopathy, and glaucoma.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: August 18, 2020
    Assignees: INSTITUTE FOR BASIC SCIENCE, KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Gou Young Koh, Jaeryung Kim, Do Young Park
  • Patent number: 10736889
    Abstract: Methods of treating patients with dyskinesias, by administering a therapeutically effective amount of a dual-action ?-opioid receptor antagonist/?-opioid receptor agonists or prodrug thereof to a subject in need thereof, sufficient to mitigate the dyskinesia. Alternatively, a combination of both a ?-opioid receptor antagonist or prodrug thereof, and a ?-opioid receptor agonist or prodrug thereof can be administered, either together or separately.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: August 11, 2020
    Assignee: Rutgers, The State University of New Jersey
    Inventors: M. Maral Mouradian, Steven Braithwaite, Michael Voronkov
  • Patent number: 10729368
    Abstract: A computer-implemented method and system can include obtaining, by at least one processor, at least one visual input comprising a face of at least one person. The at least one processor can input the at least one visual input into at least one psychodiagnostic neural network (PNN) to obtain at least one personality metric of the at least one person. The at least one personality metric of the at least one person can include at least one personality dimension and at least one numerical personality score. The at least one numerical personality score may provide a numerical indication of the strength of a particular personality dimension and display at least one personality report on at least one screen of at least one computing device. The at least one personality report may include the at least one personality metric of the at least one person.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: August 4, 2020
    Assignee: Facemetrics Limited
    Inventors: Mikhail Boiko, Aleh Arol, Dzianis Pirshtuk, Aliaksandr Vinahradau, Alex Glinsky, Pavel Kavaliou
  • Patent number: 10716862
    Abstract: The present invention provides for compositions and methods for treating, ameliorating or preventing a lysosomal storage disease by administering to a patient suffering front a lysosomal storage disease a P97 conjugated with an enzyme which is capable of transportation into the lysosomes of cells on either sides of the blood brain barrier.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: July 21, 2020
    Assignee: BiOasis Advanced Technologies Inc.
    Inventors: Christopher M. Starr, Todd Zankel
  • Patent number: 10716783
    Abstract: Methods for treating a patient suffering from neural cell injury, the method comprising administering to the patient an effective amount of a HIF prolyl-4-hydroxylase inhibiting compound having the following general formula (1) wherein R1 is a cyclic group containing at least three and up to seven carbon atoms and optionally containing one or more heteroatoms selected from O, N, and S, and optionally attached to the shown carbon atom by a linking group; R2 is independently selected from said cyclic groups of R1 and acyclic hydrocarbon groups R5 containing up to twenty carbon atoms; R3 is selected from hydrogen atom and hydrocarbon groups containing up to six carbon atoms; R6 and R7 are independently selected from hydrogen atom, hydrocarbon groups containing up to three carbon atoms, halogen atom, and polar groups, as well as methylene-linked versions thereof; and t is 0 or 1.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: July 21, 2020
    Assignee: CORNELL UNIVERSITY
    Inventors: Rajiv R. Ratan, Saravanan S. Karuppagounder
  • Patent number: 10683352
    Abstract: The present invention provides methods for treating cancer using mGluR8 inhibitors, such as mGluR8 inhibitory antibodies and small molecules. The invention also features compositions containing mGluR8 inhibitors, methods of diagnosing patients with mGluR8-associated cancer, and methods of predicting the response of cancer in a subject to treatment with mGluR8 inhibitors.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: June 16, 2020
    Assignee: Flagship Pioneering Innovations V, Inc.
    Inventors: Avak Kahvejian, Jordi Mata-Fink, Jonathan Barry Hurov, Chengyi Jenny Shu, George Huck Neubauer, Julian Alexander Stanley
  • Patent number: 10653693
    Abstract: Described herein are methods of treating cancer using one or more PRMT5 inhibitors, for example using one or more compounds of Formulae (1-5) or (A-F), pharmaceutically acceptable salts thereof, and/or pharmaceutical compositions thereof. Described herein are methods of treating cancer using one or more PRMT5 inhibitors, for example using one or more compounds of Formulae (1-5) or (A-F), pharmaceutically acceptable salts thereof, and/or pharmaceutical compositions thereof.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: May 19, 2020
    Assignees: Epizyme, Inc., Glaxosmithkline Intellectual Property Development Limited
    Inventors: Kenneth W. Duncan, Richard Chesworth, Paula Ann Boriack-Sjodin, Michael John Munchhof, Lei Jin, Elayne Penebre, Olena I. Barbash
  • Patent number: 10632173
    Abstract: This invention relates to a topical gel drug product preparation containing a composition comprising an isolated polypeptide having a carboxy-terminal amino acid sequence of an alpha connexin (ACT peptide), peptide stabilizers, excipients, buffering agents, and the like. A formulation and preparation steps are disclosed for the manufacturing of a stable, elegant, and pourable topical gel. The resulting formulation possesses long term stability suitable for aesthetic as well as therapeutic applications including the prevention of scaring and accelerated healing of wounds. Methods for treatment of chronic wounds, including chronic ulcers, are also provided.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: April 28, 2020
    Assignee: FIRSTRING RESEARCH, INC.
    Inventor: Gautam Ghatnekar
  • Patent number: 10548881
    Abstract: Conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to an HSP90 targeting moiety via a linker have been designed. Nanoparticles and microparticles comprising such conjugates can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or other diseases.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: February 4, 2020
    Assignee: TARVEDA THERAPEUTICS, INC.
    Inventors: Rajesh R. Shinde, Mark T. Bilodeau, Richard Wooster, Sudhakar Kadiyala
  • Patent number: 10478404
    Abstract: Methods, compositions, and devices to limit, modulate, insulate, and/or otherwise alter the effects of exogenous physical stimuli on cells are described herein. The cells may be removed from the body, preferably isolated, and treated ex vivo with the composition to limit the effects of physical stimuli on the cells and then returned to the patient. Alternatively, the cells may be treated in vivo. The compositions can be administered a variety of manners, such as systemically, locally or regionally.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: November 19, 2019
    Assignee: Arizona Board of Regents on behalf of the University of Arizona
    Inventor: Marvin J. Slepian
  • Patent number: 10420770
    Abstract: The present invention provides methods and compositions for improving episodic memory and treating dementia.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: September 24, 2019
    Assignee: EIP Pharma, LLC
    Inventor: John Jahangir Alam
  • Patent number: 10413522
    Abstract: The present invention relates to methods for treating brain metastasis by inhibiting gap junction functionality. It is based, at least in part, on the discovery that cancer cells expressing Protocadherin 7 and Connexin 43 form gap junctions with astrocytes that promote the growth of brain metastases, and that inhibition of Protocadherin 7 and/or Connexin 43 expression in cancer cells reduce progression of brain metastases. It is further based on the discovery that treatment with gap junction inhibitors tonabersat and meclofenamate inhibited progression of brain metastatic lesions and enhanced the anti-cancer activity of the conventional chemotherapeutic agent, carboplatin.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: September 17, 2019
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Joan Massague, Adrienne Boire, Qing Chen
  • Patent number: 10406141
    Abstract: The present invention provides a compound capable of being used as an active ingredient of an anti-cancer agent. To provide an anti-cancer agent with few side effects, an object of the present invention is to provide a compound capable of selectively inhibiting the target, i.e., DOCK1, or a salt thereof. The pyridinone compound of the present invention is represented by Formula (1): wherein R1 and R2 are the same or different, and each represents C1-6 alkyl; and R3 is a group represented by, for example, Formula (3) below: wherein R5 in the group represented by Formula (3) is hydrogen.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: September 10, 2019
    Assignee: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION
    Inventors: Yoshinori Fukui, Takehito Uruno, Motomu Kanai, Shigeki Matsunaga, Takahiro Shirai, Shigeyuki Yokoyama, Teruki Honma, Mutsuko Niino, Daisuke Takaya
  • Patent number: 10385116
    Abstract: The invention provides polymeric H-NOX proteins for the delivery of oxygen with longer circulation half-lives compared to monomeric H-NOX proteins. Polymeric H-NOX proteins extravasate into and preferentially accumulate in tumor tissue for sustained delivery of oxygen. The invention also provides the use of H-NOX proteins as radiosensitizers for the treatment of brain cancers.
    Type: Grant
    Filed: January 7, 2013
    Date of Patent: August 20, 2019
    Assignee: Omniox, Inc.
    Inventors: Gregory Kapp, Laura Serwer, Natacha Le Moan, Stephen P. L. Cary
  • Patent number: 10376506
    Abstract: The present invention relates to an opioid antagonist with ?-activity for use in treatment of depressive disorder with melancholic features. The invention further relates to the combination of an opioid antagonist with ?-activity and vortioxetine for use in treatment of depressive disorder with melancholic features. The invention also relates to pharmaceutical compositions comprising an opioid antagonist with ?-activity and vortioxetine.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: August 13, 2019
    Assignee: H. LUNDBECK A/S
    Inventors: Connie Sanchez Morillo, Gennady N. Smagin
  • Patent number: 10327452
    Abstract: The present invention pertains to an efficient and large-scale process to produce a medium-chain triglyceride composition with >95% content for C8 (caprylic acid), C10 (capric acid) and C12 (lauric acid), with the content of lauric acid at about 5% or more. The process involves fractionation of fatty acid methyl esters, which are mainly derived from coconut or palm kernel, their esterification to glycerol to synthesize medium-chain triglycerides, and refining them to significantly increase purity and make them fit for human consumption. Such composition can have important uses in food and its preparation, health supplements, cosmetics, and medicine, among others.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: June 25, 2019
    Inventor: Dean A. Lao, Jr.
  • Patent number: 10251887
    Abstract: The invention relates to therapeutic applications for compositions that reduce the level of oxidative stress on cells in vivo or in vitro. The invention describes methods for improving the therapeutic properties of stem cells. The invention also provides combination therapies that are useful to balance the oxidative microenvironment of cells in vivo or in vitro.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: April 9, 2019
    Assignee: University of Massachusetts
    Inventor: Louis M. Messina
  • Patent number: 10208167
    Abstract: A compound comprising a cyclodextrin and a monoalkoxy polyethylene glycol linked thereto through an ether bond (a “pegylated cyclodextrin”) is disclosed, as are drug delivery vehicles and pharmaceutical formulations including the same, and methods for making the compound and the drug delivery vehicle and for delivering the drug to a patient in need thereof. The method of making includes the steps of creating either a tosylated monoalkoxy polyethylene glycol or a tosylated cyclodextrin, and either reacting the tosylated monoalkoxy polyethylene glycol with a deprotonated cyclodextrin, or reacting the tosylated cyclodextrin with a deprotonated monoalkoxy polyethylene glycol. The present pegylated cyclodextrin readily forms an inclusion compound with certain drugs to protect the drug against adverse interactions with mucin (e.g., in a mucus membrane).
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: February 19, 2019
    Assignee: The Board of Trustees of the California State University
    Inventors: Yong Ba, Kim Trang Huu Nguyen
  • Patent number: 10202428
    Abstract: H—NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas O2 delivery. The engineered H—NOX proteins comprise mutations that impart altered O2 or NO ligand-binding relative to the corresponding wild-type H—NOX domain, and are operative as physiologically compatible mammalian blood O2 gas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H—NOX proteins for the treatment of any condition for which delivery of O2 is beneficial.
    Type: Grant
    Filed: October 12, 2016
    Date of Patent: February 12, 2019
    Assignee: The Regents of the University of California
    Inventors: Stephen P. L. Cary, Elizabeth M. Boon, Emily Weinert, Jonathan A. Winger, Michael A. Marletta
  • Patent number: 10196345
    Abstract: Described herein are a series of compounds having the structure of Formula I: for use in the inhibition of MAO and uses thereof for the treatment of a barrier disease, obesity, solid epithelial cell tumor metastasis, diabetes, an auto-immune and inflammatory disease or a cardiometabolic disorder.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: February 5, 2019
    Assignees: THE UNIVERSITY OF BRITISH COLUMBIA, CENTRE FOR DRUG RESEARCH AND DEVELOPMENT
    Inventors: Edward Ewald Putnins, David Scott Grierson, Ronan F.B. Gealageas, Alice Andree Valentine Devineau, Edith Mary Dullaghan
  • Patent number: 10093961
    Abstract: The invention relates to diagnosis, detection, screening, identifying and predicting methods. In various embodiments, methods of the invention include diagnosis, detection, or screening for a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia) in the subject; identifying a subject that will or is likely to respond to a therapy for a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia); and predicting therapeutic efficacy of a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia) treatment in a subject.
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: October 9, 2018
    Assignee: ESPERANCE PHARMACEUTICALS
    Inventors: Carola Leuschner, Hector Alila
  • Patent number: 10053422
    Abstract: The present invention relates to compounds for the treatment of mTOR (mammalian Target Of Rapamycin) pathway related diseases. Specifically, the present invention relates to the use of aminoacetonitrile derivatives (AADs) in the treatment of mTOR pathway related diseases.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: August 21, 2018
    Assignee: Pitney Pharmaceuticals Pty Limited
    Inventors: Mohammad Hossein Pourgholami, David L. Morris, Roger Aston
  • Patent number: 10047137
    Abstract: The present invention pertains to antibodies against a novel isoform of human PD1 protein (?42PD1) that contains a 42-nucleotide in-frame deletion in exon 2. The invention also pertains to methods of using the antibodies against ?42PD1 for the treatment for autoimmune disorders. In certain embodiments, the antibodies against ?42PD1 are monoclonal.
    Type: Grant
    Filed: April 7, 2014
    Date of Patent: August 14, 2018
    Assignee: VERSITECH LIMITED
    Inventors: Zhiwei Chen, Lin Cheng, Allen Ka Loon Cheung, Jingying Zhou
  • Patent number: 9945853
    Abstract: The present disclosure highlights the relationship between extracellular mitochondrial components, optionally in combination with the secreted phospholipase A2-IIA and/or an auto-antibody, and in vivo as well as in vitro and inflammatory reactions/conditions, especially those released as a result of the degradation of a platelet. The present disclosure provides methods for determining the presence of inflammatory mediators, for limiting inflammatory reactions/conditions, for the diagnosis inflammatory reactions/conditions, for screening therapeutics for the treatment and/or the alleviation of symptoms of inflammatory reactions/conditions based on the detection or modulation of the level of these extracellular mitochondrial components.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: April 17, 2018
    Assignees: Université Laval, Hérma-Québec, University of Washington
    Inventors: Eric Boilard, Luc Boudreau, Louis Thibault, Michael Herman Gelb
  • Patent number: 9918980
    Abstract: Methods of treating patients with dyskinesias, by administering a therapeutically effective amount of a dual-action ?-opioid receptor antagonist/?-opioid receptor agonists or prodrug thereof to a subject in need thereof, sufficient to mitigate the dyskinesia. Alternatively, a combination of both a mu-opioid receptor antagonist or prodrug thereof, and a kappa-opioid receptor agonist or prodrug thereof can be administered, either together or separately.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: March 20, 2018
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: M. Maral Mouradian, Steven Braithwaite, Michael Voronkov
  • Patent number: 9913864
    Abstract: The invention features compositions comprising agents having cardiac protective activity isolated from epicardial progenitor cells and derivatives thereof, and methods for the use of such compositions.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: March 13, 2018
    Assignee: THE UNIVERSITY OF VERMONT AND STATE AGRICULTURE COLLEGE
    Inventor: Jeffrey Spees
  • Patent number: 9885083
    Abstract: Accordingly, in some embodiments methods for detecting an analyte or analytes in one or more sample(s) are provided. The methods encompass providing a solid support with an addressable marker and an associated ligand, contacting the solid substrate to a sample, thereby forming a contacted solid support, associating the contacted solid support with a FET array and detecting the electrical properties of the FET array and thereby detecting an analyte or analytes in one or more samples. In other embodiments, the sample encompasses a second addressable marker.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: February 6, 2018
    Assignee: Life Technologies Corporation
    Inventors: Scott Conradson, David Dinauer, Bin Zhao, Dmitriy Gremyachinskiy, Jason Myers, Jeffrey Rossio, Victoria Singer, Kristina Giorda
  • Patent number: 9861652
    Abstract: 2?-Fluoro-nucleoside compounds are disclosed which are useful in the treatment of hepatitis B infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer. The compounds have the general formulae: wherein Base is a purine or pyrimidine base; R1 is OH, H, OR3, N3, CN, halogen, CF3, lower alkyl, amino, loweralkylamino, di(lower)alkylamino, or alkoxy; R2 is H, phosphate, or a stabilized phosphate prodrug; acyl, or other pharmaceutically acceptable leaving benzyl, a lipid, an amino acid, peptide, or cholesterol; and R3 is acyl, alkyl, phosphate, or other pharmaceutically acceptable leaving group; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: January 9, 2018
    Assignees: Emory University, The University of Georgia Research Foundation, Inc.
    Inventors: Raymond F. Schinazi, Dennis C. Liotta, Chung K. Chu, J. Jeffrey McAtee, Junxing Shi, Yongseok Choi, Kyeong Lee, Joon H. Hong
  • Patent number: 9861736
    Abstract: Methods are provided for collecting platelet-rich plasma. A disposable flow circuit is mounted to a fluid processing device having a fluid separation chamber and an injection device. A fluid containing plasma and platelets is continuously conveyed from a fluid source into the fluid separation chamber and processed to produce platelet-rich plasma. At least a portion of the platelet-rich plasma is automatically conveyed from the fluid separation chamber into the injection device, which is directly connected to a pump device such that at least a portion of the platelet-rich plasma from the fluid separation chamber is automatically conveyed into the pump device prior to being conveyed into the injection device. The injection device with the platelet-rich plasma is then detached from the disposable flow circuit.
    Type: Grant
    Filed: May 31, 2013
    Date of Patent: January 9, 2018
    Assignee: Fenwal, Inc.
    Inventors: John W. Barry, Jr., Brian C. Case, Jonathan Prendergast, Lan T. Nguyen, John Foley
  • Patent number: 9758786
    Abstract: Provided herein are composition for sensitizing tumors to anti-tumor therapies. The compositions include antisense oligonucleotides against TGF?2, wherein the compositions sensitize tumors to anti-tumor therapies. Also provided herein are method for treating cancer using the compositions described herein.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: September 12, 2017
    Assignee: AUTOTELIC, LLC
    Inventor: Vuong Trieu
  • Patent number: 9695462
    Abstract: The present invention is related to a method for evaluation of drug efficacy of a medicine having a therapeutic or preventive effect against a disease related to EL activity wherein phosphatidylinositol or lysophosphatidylinositol is used as an indicator. The present invention is also related to a method for screening an inhibitor of EL activity using phosphatidylinositol and a kit for use in the method.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: July 4, 2017
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Takashi Ono, Atsuko Yamamoto, Shuhei Shigaki
  • Patent number: 9689029
    Abstract: The invention provides systems and methods for processing samples. In a method, a reaction card is provided that has a channel network, a valve, and a micropump, all disposed within the card. The reaction card also has a collection well disposed on a surface of the card and a tubular member extending out from the card. A reaction vessel is provided and affixed to the reaction card such that the tubular member is inserted into the reaction vessel. Amplification reaction reagents and a sample are delivered into the reaction vessel, and an amplification reaction is initiated within the reaction vessel, resulting in an amplification product being disposed within the reaction vessel. The valve is opened to atmosphere, and the first micropump is activated to pump an aliquot of reaction product from the reaction vessel into the tubular member, through the channel network, and into the collection well.
    Type: Grant
    Filed: November 29, 2012
    Date of Patent: June 27, 2017
    Assignee: Caliper Life Sciences, Inc.
    Inventors: Edward H. Thorne, IV, Abbie L. Esterman
  • Patent number: 9670288
    Abstract: Methods for treating neurodegeneration, e.g., sensorineural hearing loss, or a demyelinating disease, using bisphosphonates, ERK kinase inhibitors, and osteoprotegerin (OPG) proteins or nucleic acids.
    Type: Grant
    Filed: March 18, 2014
    Date of Patent: June 6, 2017
    Assignee: Massachusetts Eye and Ear Infirmary
    Inventors: Konstantina Stankovic, Michael McKenna, Shyan-Yuan Kao, Albert Edge
  • Patent number: 9656986
    Abstract: In one embodiment, the present application discloses mixtures comprising (a) water in an amount of at least 1% wt/wt of the mixture; (b) a transition metal catalyst; and (c) one or more solubilizing agents; and methods for using such mixtures for performing transition metal mediated bond formation reactions.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: May 23, 2017
    Assignee: MYCELL TECHNOLOGIES, LLC
    Inventor: Volker Berl
  • Patent number: 9651562
    Abstract: Method of diagnosing and treating inflammatory bowel disease are disclosed herein. Inflammatory bowel disease can be treated and diagnosed using cathelicidin peptides and detection agents thereof. Specifically, method of treating and diagnosing Crohn's disease and ulcerative colitis are disclosed herein.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: May 16, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Hon Wai Koon, Charalabos Pothoulakis
  • Patent number: 9622947
    Abstract: The present invention relates to a foamable vehicle or cosmetic or pharmaceutical composition, comprising: (1) an organic carrier, at a concentration of 10% to 70% by weight, wherein said organic carrier concurrently comprises: (i) at least one hydrophobic organic carrier, and (ii) at least one polar solvent; (2) at least one surface-active agent; (3) water; and (4) at least one liquefied or compressed gas propellant at a concentration of 3% to 25% by weight of the total composition. The present invention further provides a method of treating, alleviating or preventing a disorder of mammalian subject, comprising administering the above-mentioned compositions to an afflicted target site.
    Type: Grant
    Filed: January 8, 2009
    Date of Patent: April 18, 2017
    Assignee: Foamix Pharmaceuticals Ltd.
    Inventors: Dov Tamarkin, Doron Friedman, Meir Eini, Alex Besonov